An act relating to health insurance coverage for diabetes treatment

2025-2026 Regular Session Introduced by Carolyn Branagan

The bill requires health plans in Vermont to cover a broad range of diabetes treatments and supplies with protections to reduce out-of-pocket costs and ensure access.

Read first time and referred to the Committee on Health Care

Summary of H 207 (2025-2026) – Vermont

Purpose and intent

H 207 aims to improve health insurance coverage for diabetes treatment in Vermont. By specifying coverage requirements and related protections, the bill seeks to reduce out-of-pocket costs and expand access to essential diabetes management services and supplies for insured individuals.

Key provisions and changes

Diabetes care coverage mandates: The bill requires health insurance plans to cover a range of diabetes-related treatments and supplies. This typically includes items such as:

Insulin and non-insulin injectable medications (as applicable)
Oral diabetes medications
Glucose meters and testing supplies
Continuous glucose monitors (CGMs) and related accessories
Diabetes self-management education and training (DSME/T)
Diabetes management software or apps, if prescribed
Durable medical equipment (e.g., insulin pumps, pump supplies) when medically necessary

Cost-sharing protections: Provisions may limit deductibles, copayments, or coinsurance for covered diabetes supplies and services to ensure affordability for patients.

Formulary and adequacy standards: The bill may require that coverage be provided without discrimination against medically necessary diabetes treatments and that plans maintain formulary adequacy to ensure access to prescribed therapies.

Prior authorization and step therapy: If included, the bill could streamline or prohibit unnecessary delays by restricting burdensome prior authorization or step therapy for essential diabetes medications and supplies.

Special populations and exemptions: Provisions could address coverage for vulnerable groups (e.g., pediatric patients, those with Medicaid/State exchanges) and ensure continuity of care during plan changes or transitions.

Regulatory alignment and enforcement: The bill would align with existing state health insurance regulations and may establish oversight mechanisms or penalties for noncompliance.

Who would be affected

Individuals with diabetes enrolled in private or public health insurance plans operating in Vermont, including those buying through the state exchange.

Health insurers and plan sponsors offering individual, small group, or larger group policies in Vermont.

Healthcare providers and suppliers (e.g., pharmacies, durable medical equipment providers, diabetes educators) who deliver covered treatments and supplies.

State agencies administering health and insurance programs, which may implement, monitor, and enforce the new coverage requirements.

Procedural and timeline aspects

Introduction and referral: The bill was read in the House and referred to the Committee on Health Care on February 12, 2025.

Sponsor: Co-sponsored by Carolyn Branagan.

Next steps (typical timeline): If advanced, the bill would undergo committee analysis, potential amendments, and votes in the House, followed by consideration by the Senate and reconciliation as needed, with any enacted provisions subject to signing by the governor or legislative override processes.

Notes

The available information provides the bill’s title, purpose category, initial referral date, and a co-sponsor. Specific statutory text, dollar amounts, or detailed sub-provisions are not included in the provided summary and would be clarified in the committee draft and subsequent legislative actions.